Patents for A61P 35 - Antineoplastic agents (221,099)
12/2003
12/16/2003US6663857 In vivo gene transfer using implanted retroviral producer cells
12/16/2003US6663856 Gene therapy
12/16/2003US6663659 Method and apparatus for the photomodulation of living cells
12/16/2003CA2286879C Novel method for the production of anti-human antigen receptors and uses thereof
12/16/2003CA2157114C Process for the preparation of 9-desoxotaxanes
12/16/2003CA2134751C Monoclonal antibodies and their use
12/16/2003CA2113894C A process for the preparation of demethylepypodophyllotoxin
12/14/2003CA2432496A1 Diagnostic and therapeutic uses of sufu gene
12/11/2003WO2003102588A2 Diagnostic agent, method for detecting a carcinoma, and means for the treatment thereof
12/11/2003WO2003102584A2 Semaphorin-like proteins and methods of using same
12/11/2003WO2003102576A1 POLYUBIQUITINATION OF RB CATALYZED BY Mdm2
12/11/2003WO2003102207A2 Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments
12/11/2003WO2003102188A1 Mutated androgen receptor, cancer cells expressing the same, method of constructing the same and use thereof
12/11/2003WO2003102187A1 Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence
12/11/2003WO2003102180A1 NOVEL PEPTIDES HAVING cAMP PRODUCING ACTIVITY
12/11/2003WO2003102151A2 Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors
12/11/2003WO2003102148A2 Human prolactin antagonist-angiogenesis inhibitor fusion proteins
12/11/2003WO2003102028A1 Rb1 gene induced protein (rb1cc1) and gene
12/11/2003WO2003101996A2 Esters in position 20 of camptothecins
12/11/2003WO2003101995A2 Camptothecins with a modified lactone ring
12/11/2003WO2003101991A1 Xanthine phosphodiesterase v inhibitor polymorphs
12/11/2003WO2003101989A1 Inhibitors of jak and cdk2 protein kinases
12/11/2003WO2003101987A1 3-substituted quinuclidines and their use
12/11/2003WO2003101985A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders
12/11/2003WO2003101984A1 Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same
12/11/2003WO2003101980A1 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors
12/11/2003WO2003101978A1 Phenyl-thiophene type vitamin d receptor modulators
12/11/2003WO2003101970A1 Imidazolium cxcr3 inhibitors
12/11/2003WO2003101951A2 Triptolide derivatives for modulation of apoptosis and immunosuppression
12/11/2003WO2003101932A2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/11/2003WO2003101927A1 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
12/11/2003WO2003101919A2 Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
12/11/2003WO2003101530A2 Solid hydrogel coupling for ultrasound imaging and therapy
12/11/2003WO2003101495A1 Methods and compositions for radioimmunotherapy of brain and cns tumors
12/11/2003WO2003101491A1 PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
12/11/2003WO2003101486A2 Thermosensitive polymer carriers having a modifiable physical structure for biochemical analysis, diagnosis, and therapy
12/11/2003WO2003101479A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
12/11/2003WO2003101475A1 Treatment of cell proliferative disorders with chlorotoxin
12/11/2003WO2003101474A1 Combination chemotherapy with chlorotoxin
12/11/2003WO2003101470A1 Pharmaceutical composition containing arsenic trioxide and at least one long-chain, polyunsaturated fatty acid
12/11/2003WO2003101468A1 Method for the protection of endothelial and epithelial cells during chemotherapy
12/11/2003WO2003101466A1 Rubrofusarin glycoside-containing composition
12/11/2003WO2003101465A1 Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same
12/11/2003WO2003101456A1 Use of compounds that stimulate cgmp
12/11/2003WO2003101455A2 Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
12/11/2003WO2003101453A1 Triple monoamine reuptake inhibitors for the treatment of chronic pain
12/11/2003WO2003101451A1 Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue
12/11/2003WO2003101450A1 N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris
12/11/2003WO2003101446A1 A herbal molecule as potential anti-leukemic drug
12/11/2003WO2003101444A1 Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
12/11/2003WO2003101425A2 Therapeutic agent-containing polymeric nanoarticles
12/11/2003WO2003101406A1 Homo-camptothecin derivatives
12/11/2003WO2003101386A2 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
12/11/2003WO2003101383A2 Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
12/11/2003WO2003101375A2 Immunostimulatory oligonucleotides and uses thereof
12/11/2003WO2003101374A2 Use of new etonogestrel esters
12/11/2003WO2003084984A8 Heterocyclic amides with alpha-4 integrin antagonist activity
12/11/2003WO2003080566A3 Hif hydroxylase inhibitors
12/11/2003WO2003074568A9 Individualized anti-cancer antibodies
12/11/2003WO2003070265A3 Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis
12/11/2003WO2003064463A3 Pluripotency determining factors and uses thereof
12/11/2003WO2003057666A3 Inhibitors of dipeptidyl peptidase iv
12/11/2003WO2003051289A3 Solubilized topoisomerase poison agents
12/11/2003WO2003048306A3 Polycistronic expression of antibodies
12/11/2003WO2003044053A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/11/2003WO2003043632A3 Use of bisindolmaleimide and gemcitabine for the treatment of cancer
12/11/2003WO2003040365A3 Pna-conjugate or pna-conjugate mixture for treating diseases related to the human papillomavirus
12/11/2003WO2003038037A3 Glycogen synthase kinase function in endothelial cells
12/11/2003WO2003037266A3 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
12/11/2003WO2003035104A3 Compositions and methods for selected tumor treatment
12/11/2003WO2003029825A3 Method for predicting the sensitivity to chemotherapy
12/11/2003WO2003029407A3 Isolated nucleic acid molecules encoding a bacterial uracil transport protein and a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
12/11/2003WO2003028721A3 Substituted benzimidazole compounds and their use for the treatment of cancer
12/11/2003WO2003027090A3 Bicyclic heterocycles as rxr ligands
12/11/2003WO2003024926A3 Methods and compositions of novel triazine compounds
12/11/2003WO2003024395A3 Linked biaryl compounds
12/11/2003WO2003023042A9 Recombinant mva capable of expressing structural hcv antigens
12/11/2003WO2003022883A3 Use of proteins for the production of a medicament for stimulating the innate non specific immune system
12/11/2003WO2003022216A3 Biaryl substituted purine derivatives as potent antiproliferative agents
12/11/2003WO2003018014A9 Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives
12/11/2003WO2003017940A3 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption
12/11/2003WO2003011895A8 Compositions and methods for modulation of immune responses
12/11/2003WO2003011226A3 Products and drug delivery vehicles
12/11/2003WO2003003975A3 Detection and therapy of vulnerable plaque with photodynamic compounds
12/11/2003WO2003002142A8 Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
12/11/2003WO2002094176A3 Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments
12/11/2003WO2002087508A3 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
12/11/2003WO2002087465A3 Compositions and methods of double-targeting virus infections and cancer cells
12/11/2003WO2002085925A3 Melanocortin receptor ligands
12/11/2003WO2002083841A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/11/2003WO2002083067A3 Prodrugs via acylation with cinnamate
12/11/2003WO2002081506A8 Process for producing trunkamide a compounds
12/11/2003WO2002072013A3 Method of treating malignancies through induction of blood immune responses
12/11/2003WO2002067986A3 Symbiotic regenerative agent
12/11/2003WO2002064788A3 Compositions and methods relating to lung specific genes and proteins
12/11/2003WO2002060383A3 Cancer therapy
12/11/2003WO2002053149A3 Medicament containing a polyamine as an active substance
12/11/2003WO2002048191A3 Inhibitory agents derived from specific growth factors
12/11/2003WO2002048165A8 Antiviral agents for treatment of flaviviridae infections
12/11/2003WO2002008174A8 Phenylethylamine derivatives and their use in the treatment of melanoma